{
    "Trade/Device Name(s)": [
        "VITEK 2 AST-GN Ceftolozane/Tazobactam"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K161510",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121546"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTW",
        "LTT"
    ],
    "Summary Letter Date": "February 13, 2017",
    "Summary Letter Received Date": "January 13, 2017",
    "Submission Date": "May 31, 2016",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Ceftolozane/Tazobactam"
    ],
    "Specimen Type(s)": [
        "Isolated colonies"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VITEK 2",
        "VITEK 2 Compact"
    ],
    "Method(s)/Technology(ies)": [
        "Minimum inhibitory concentration (MIC) microdilution"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Automated quantitative/qualitative susceptibility testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Card"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK 2 AST-GN Ceftolozane/Tazobactam antimicrobial susceptibility testing card for automated MIC determination.",
    "Indications for Use Summary": "Designed for antimicrobial susceptibility testing of Gram negative bacilli with VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in determining in vitro susceptibility to ceftolozane/tazobactam.",
    "fda_folder": "Microbiology"
}